Document Detail

Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
MedLine Citation:
PMID:  12081988     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Although effects of statins on cardiovascular outcomes are well established in men, fewer data exist for women. Furthermore, the effects of statins plus hormone replacement therapy (HRT) on cardiovascular outcomes are uncertain. METHODS AND RESULTS: We examined statin use, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS), a randomized clinical trial of estrogen plus progestin versus placebo in postmenopausal women with heart disease (n=2763). A nonrandomized comparison of statin users and nonusers revealed lower rates of the primary outcome, nonfatal myocardial infarction or coronary heart disease death (relative hazard [RH]=0.79, 95% confidence intervals [CI] 0.63 to 0.99, P=0.04), and total mortality (RH=0.67, 95% CI 0.51 to 0.87, P=0.003). Rates of venous thromboembolic events were also lower among statin users (RH=0.45, 95% CI 0.23 to 0.88, P=0.02). HRT resulted in a significant increase in early risk for primary events in women who did not use statins (RH=1.75, 95% CI 1.02 to 3.03, P=0.04) but not in statin users (RH=1.34, 95% CI 0.63 to 2.86, P=0.45). Adjustment for postrandomization statin use showed no effect of HRT on risk for the primary outcome (RH=0.96, 95% CI 0.77 to 1.29; P=0.72). CONCLUSIONS: In HERS, statin use was associated with lower rates of cardiovascular events, venous thromboembolic events, and total mortality. These data provide strong support for statin use in eligible women with coronary disease.
David M Herrington; Eric Vittinghoff; Feng Lin; Josephine Fong; Fran Harris; Donald Hunninghake; Vera Bittner; Helmut G Schrott; Roger S Blumenthal; Robert Levy;
Related Documents :
12364448 - Hormone replacement effects on endothelial function measured in the forearm resistance ...
8896888 - Hormone replacement therapy is associated with lower risk of adenomatous polyps of the ...
2070578 - The mammographic parenchymal patterns of women on hormonal replacement therapy.
18590478 - Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, u...
21233088 - Factors associated with genitourinary medicine clinic attendance and sexually transmitt...
25211418 - History of syphilis in women living with aids and associated risk factors in são paulo...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  105     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-25     Completed Date:  2002-07-08     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2962-7     Citation Subset:  AIM; IM    
Department of Internal Medicine/Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / prevention & control*
Coronary Disease / drug therapy*,  mortality*
Drug Interactions
Estrogen Replacement Therapy*
Estrogens, Conjugated (USP) / therapeutic use
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Medroxyprogesterone Acetate / therapeutic use
Myocardial Infarction / epidemiology,  prevention & control
Thromboembolism / epidemiology,  prevention & control
Reg. No./Substance:
0/Estrogens, Conjugated (USP); 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertens...
Next Document:  Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is a...